TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF GLOBAL BLOOD SCREENING MARKET 30
1.4 CURRENCY AND PRICING 31
1.5 LIMITATION 32
1.6 MARKETS COVERED 32
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHIC SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 CURRENCY AND PRICING 38
2.5 RESEARCH METHODOLOGY 39
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.7 DBMR MARKET POSITION GRID 43
2.8 THE CATEGORY VS TIME GRID 44
2.9 THE CATEGORY VS TIME GRID 45
2.10 DBMR MARKET CHALLENGE MATRIX 46
2.11 SECONDARY SOURCES 47
2.12 ASSUMPTIONS 47
3 MARKET OVERVIEW 48
3.1 DRIVERS 50
3.1.1 RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS 50
3.1.2 RISING PREVALENCE IN NUMBER OF DISEASES 50
3.1.3 RISING NUMBER OF INITIATIVES BY VARIOUS GOVERNMENTS AND GOVERNMENT ASSOCIATIONS 51
3.2 RESTRAINTS 52
3.2.1 LACK OF USING NAT TECHNLOGY IN EMERGING COUNTRIES 52
3.2.2 HIGH COST OF TECHNOLOGY AND INSTRUMENTS 52
3.2.3 EMERGING ALTERNATIVE TECHNOLOGIES 53
3.3 OPPORTUNITIES 54
3.3.1 INCREASING MICROBIOLOGY SCREENING & MULTIPLEXING 54
3.4 CHALLENGES 55
3.4.1 REDUCTION IN PRICE FOR TECHNOLOGY AND INSTRUMENT 55
4 EXECUTIVE SUMMARY 56
5 PREMIUM INSIGHTS 60
6 GLOBAL BLOOD SCREENING MARKET, BY PRODUCTS & SERVICES 63
6.1 OVERVIEW 64
6.2 REAGENTS & KITS 66
6.2.1 ELISA REAGENTS & KITS 68
6.2.1.1 IMMUNOSORBENTS 69
6.2.1.2 CONJUGATES 69
6.2.1.3 SUBSTRATES 69
6.2.1.4 CONTROLS 69
6.2.1.5 SAMPLE DILUENTS AND WASH SOLUTIONS 69
6.2.2 NAT REAGENTS & KITS 69
6.2.2.1 PROBES AND PRIMERS 70
6.2.2.2 ENZYMES AND POLYMERASES 70
6.2.2.3 LABELING AND DETECTION REAGENTS 70
6.2.2.4 STANDARDS AND CONTROLS 70
6.2.2.5 BUFFERS, NUCLEOTIDES AND SOLUTIONS 70
6.3 INSTRUMENTS 71
6.3.1.1 INSTRUMENTS, PRODUCT TYPE 72
6.3.1.1.1 SEMI AUTOMATED 72
6.3.1.1.2 AUTOMATED 72
6.3.1.2 INSTRUMENTS, PURCHASE TYPE 72
6.3.1.2.1 OUTRIGHT PURCHASE 72
6.3.1.2.2 RENTAL 72
6.4 SOFTWARE & SERVICES 73
7 GLOBAL BLOOD SCREENING MARKET, BY TECHNOLOGY 74
7.1 OVERVIEW 75
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 77
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY PLATFORM 79
7.2.1.1 COLORIMETRIC IMMUNOASSAY (CI) 79
7.2.1.2 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) 79
7.2.1.3 FLUORESCENCE IMMUNOASSAY (FIA) 79
7.2.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY GENERATIONS 79
7.2.2.1 FIRST-GENERATION ELISA 79
7.2.2.2 SECOND-GENERATION ELISA 79
7.2.2.3 THIRD-GENERATION ELISA 79
7.2.2.4 FOURTH-GENERATION ELISA 79
7.3 RAPID TESTS 80
7.4 NEXT-GENERATION SEQUENCING (NGS) 81
7.5 NUCLEIC ACID TEST 82
7.5.1 REAL-TIME POLYMERASE CHAIN REACTION (PCR) 83
7.5.2 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 83
7.6 WESTERN BLOT ASSAY 84
7.7 OTHERS 85
8 GLOBAL BLOOD SCREENING MARKET, BY DISEASE TYPE 86
8.1 OVERVIEW 87
8.2 ONCOLOGY 89
8.3 DIABETES MELLITUS 90
8.4 COLD & FLU 91
8.5 CHOLESTEROL 92
8.6 INFECTIOUS DISEASES 93
8.7 RESPIRATORY DISEASES 94
8.8 HIV/AIDS 95
8.9 OTHERS 96
9 GLOBAL BLOOD SCREENING MARKET, BY END USER 97
9.1 OVERVIEW 98
9.2 DIAGNOSTIC CENTERS 100
9.3 BLOOD BANK 101
9.4 HOSPITALS 102
9.5 CLINICS 103
9.6 AMBULATORY SURGICAL CENTERS 104
10 GLOBAL BLOOD SCREENING MARKET, BY GEOGRAPHY 105
10.1 OVERVIEW 106
10.2 NORTH AMERICA 111
10.2.1 U.S. 121
10.2.2 CANADA 128
10.2.3 MEXICO 135
10.3 EUROPE 142
10.3.1 GERMANY 153
10.3.2 U.K. 160
10.3.3 FRANCE 167
10.3.4 ITALY 174
10.3.5 SPAIN 181
10.3.6 SWITZERLAND 188
10.3.7 NETHERLANDS 195
10.3.8 BELGIUM 202
10.3.9 RUSSIA 209
10.3.10 TURKEY 216
10.3.11 REST OF EUROPE 223
10.4 ASIA-PACIFIC 224
10.4.1 CHINA 235
10.4.2 JAPAN 242
10.4.3 SOUTH KOREA 249
10.4.4 INDIA 256
10.4.5 SINGAPORE 263
10.4.6 AUSTRALIA 270
10.4.7 THAILAND 277
10.4.8 MALAYSIA 284
10.4.9 INDONESIA 291
10.4.10 PHILIPPINES 298
10.4.11 REST OF ASIA-PACIFIC 305
10.5 SOUTH AMERICA 306
10.5.1 BRAZIL 316
10.5.2 REST OF SOUTH AMERICA 323
10.6 MIDDLE EAST & AFRICA 324
10.6.1 SOUTH AFRICA 334
10.6.2 REST OF MIDDLE EAST & AFRICA 341
11 GLOBAL BLOOD SCREENING MARKET, COMPANY LANDSCAPE 342
11.1 COMPANY SHARE ANALYSIS; GLOBAL 342
11.2 COMPANY SHARE ANALYSIS; NORTH AMERICA 343
11.3 COMPANY SHARE ANALYSIS; EUROPE 344
11.4 COMPANY SHARE ANALYSIS; ASIA-PACIFIC 345
12 COMPANY PROFILES 346
12.1 F. HOFFMANN-LA ROCHE LTD 346
12.1.1 COMPANY OVERVIEW 346
12.1.2 REVENUEANALYSIS 346
12.1.3 COMPANY SHARE ANALYSIS 347
12.1.4 PRODUCT PORTFOLIO 347
12.1.5 RECENT DEVELOPMENT 348
12.2 ABBOTT 349
12.2.1 COMPANY OVERVIEW 349
12.2.2 REVENUE ANALYSIS 349
12.2.3 COMPANY SHAREV ANALYSIS 350
12.2.4 PRODUCT PORTFOLIO 350
12.2.5 RECENT DEVELOPMENT 351
12.3 THERMO FISHER SCIENTIFIC INC. 352
12.3.1 COMPANY OVERVIEW 352
12.3.2 REVENUE ANALYSIS 352
12.3.3 COMPANY SHAREV ANALYSIS 353
12.3.4 PRODUCT PORTFOLIO 353
12.3.5 RECENT DEVELOPMENTS 354
12.4 SIEMENS AG 355
12.4.1 COMPANY OVERVIEW 355
12.4.2 REVENUE ANALYSIS 355
12.4.3 COMPANY SHAREV ANALYSIS 356
12.4.4 PRODUCT PORTFOLIO 356
12.4.5 RECENT DEVELOPMENTS 358
12.5 BIO-RAD LABORATORIES, INC. 359
12.5.1 1.3.1COMPANY OVERVIEW 359
12.5.2 REVENUE ANALYSIS 359
12.5.3 COMPANY SHAREV ANALYSIS 360
12.5.4 PRODUCT PORTFOLIO 360
12.5.5 RECENT DEVELOPMENTS 362
12.6 BD 363
12.6.1 COMPANY OVERVIEW 363
12.6.2 REVENUE ANALYSIS 363
12.6.3 PRODUCT PORTFOLIO 364
12.6.4 RECENT DEVELOPMENTS 364
12.7 BECKMAN COULTER, INC. 365
12.7.1 COMPANY OVERVIEW 365
12.7.2 GEOGRAPHICPRESENCE 365
12.7.3 PODUCT PORTFOLIO 366
12.7.4 RECENET DEVELOPEMENTS 367
12.8 BIOM?RIEUX SA 368
12.8.1 COMPANY OVERVIEW 368
12.8.2 REVENUE ANALYSIS 368
12.8.3 PRODUCT PORTFOLIO 369
12.8.4 RECENT DEVELOPMENT 370
12.9 CEPHEID (A SUBSIDIARY OF DANAHER CORPORATION) 371
12.9.1 COMPANY OVERVIEW 371
12.9.2 GEOGRAPHIC PRESENCE 371
12.9.3 PRODUCT PORTFOLIO 372
12.9.4 RECENT DEVELOPMENT 373
?
12.10 ENZO BIOCHEM INC. 374
12.10.1 COMPANY OVERVIEW 374
12.10.2 REVENUE ANALYSIS 374
12.10.3 PRODUCT PORTFOLIO 375
12.10.4 RECENT DEVELOPMENTS 376
12.11 GRIFOLS INTERNATIONAL, S.A. 377
12.11.1 COMPANY OVERVIEW 377
12.11.2 REVENUE ANALYSIS 377
12.11.3 PRODUCT PORTFOLIO 378
12.11.4 RECENT DEVELOPMENTS 379
12.12 HOLOGIC INC. 380
12.12.1 COMPANY OVERVIEW 380
12.12.2 REVENUE ANALYSIS 380
12.12.3 PRODUCT PORTFOLIO 381
12.12.4 RECENT DEVELOPMENTS 381
12.13 IMMUCOR, INC. 382
12.13.1 COMPANY OVERVIEW 382
12.13.2 GEOGRAPHIC PRESENCE; 382
12.13.3 PRODUCT PORTFOLIO 383
12.13.4 RECENT DEVELOPMENTS 384
12.14 MERIDIAN BIOSCIENCE, INC. 385
12.14.1 COMPANY OVERVIEW 385
12.14.2 REVENUE ANALYSIS 385
12.14.3 PRODUCT PORTFOLIO 386
12.14.4 RECENT DEVELOPMENTS 387
12.15 ORTHO CLINICAL DIAGNOSTICS 388
12.15.1 COMPANY OVERVIEW 388
12.15.2 GEOGRAPHIC PRESENCE 388
12.15.3 PRODUCT PORTFOLIO 389
12.15.4 RECENT DEVELOPMENTS 390
13 RELATED REPORTS 391